Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China

Research in Microbiology

Volumn 166, Issue 3, 2015, Pages 153-161

  Liu, Jin Yan ^a   Shi, Ce ^a   Wang, Ying ^a   Li, Wen Jing ^a   Zhao, Yue ^a   Xiang, Ming Jie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biosynthetic pathway; Efflux pumps; ERG11; Ergosterol; Transcription factor; Triazole resistance

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 6G; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE; VORICONAZOLE; LANOSTEROL; PYRROLE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BINDING AFFINITY; BIOSYNTHESIS; CANDIDA ALBICANS; CHINA; CONTROLLED STUDY; ERG11 GENE; ERG3 GENE; FLOW CYTOMETRY; FUNGAL CELL; FUNGAL GENE; FUNGUS ISOLATION; MASS FRAGMENTOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STEROL ANALYSIS; TAC1 GENE; DNA SEQUENCE; DRUG EFFECTS; GENE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION;

CANDIDA ALBICANS;

AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CHINA; DRUG RESISTANCE, FUNGAL; ERGOSTEROL; FLOW CYTOMETRY; FLUCONAZOLE; GENES, FUNGAL; GENES, MDR; HUMANS; LANOSTEROL; MUTATION, MISSENSE; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84926407087     PISSN: 09232508     EISSN: 17697123     Source Type: Journal    
DOI: 10.1016/j.resmic.2015.02.009     Document Type: Article

References (29)

1. Kim J., Sudbery P. Candida albicans, a major human fungal pathogen. J Microbiol 2011, 49:171-177.
2. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
3. Pfaller M.A., Moet G.J., Messer S.A., Jones R.N., Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol 2011, 49:396-399.
4. Guo F., Yang Y., Kang Y., Zang B., Cui W., Qin B., et al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study. J Antimicrob Chemother 2013, 68:1660-1668.
5. Xia H., Wu H., Xia S., Zhu X., Chen C., Qiu G., et al. Invasive Candidiasis in preterm neonates in China: a retrospective study from 11 NICUS during 2009-2011. Pediatr Infect Dis J 2014, 33:106-109.
6. Liu W., Tan J., Sun J., Xu Z., Li M., Yang Q., et al. Invasive candidiasis in intensive care units in China: invitro antifungal susceptibility in the China-SCAN study. J Antimicrob Chemother 2014, 69:162-167.
7. Yang Z.T., Wu L., Liu X.Y., Zhou M., Li J., Wu J.Y., et al. Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in Shanghai. BMC Infect Dis 2014, 14:241.
8. Pappas P.G., Kauffman C.A., andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
9. Tsao S., Rahkhoodaee F., Raymond M. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob Agents Chemother 2009, 53:1344-1352.
10. Morio F., Loge C., Besse B., Hennequin C., Le Pape P. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 2010, 66:373-384.
11. Helmerhorst E.J., Murphy M.P., Troxler R.F., Oppenheim F.G. Characterization of the mitochondrial respiratory pathways in Candida albicans. Biochim Biophys Acta 2002, 1556:73-80.
12. Morio F., Pagniez F., Lacroix C., Miegeville M., Le Pape P. Amino acid substitutions in the Candida albicans sterol Delta5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. J Antimicrob Chemother 2012, 67:2131-2138.
13. Perea S., Lopez-Ribot J.L., Kirkpatrick W.R., McAtee R.K., Santillan R.A., Martinez M., et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001, 45:2676-2684.
14. Goldman G.H., da Silva Ferreira M.E., dos Reis Marques E., Savoldi M., Perlin D., Park S., et al. Evaluation of fluconazole resistance mechanisms in candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 2004, 50:25-32.
15. Morio F., Pagniez F., Besse M., Gay-andrieu F., Miegeville M., Le Pape P. Deciphering azole resistance mechanisms with a focus on transcription factor-encoding genes TAC1, MRR1 and UPC2 in a set of fluconazole-resistant clinical isolates of Candida albicans. Int J Antimicrob Agents 2013, 42:410-415.
16. Standards NCCLS Reference method for broth dilution antifungal susceptibility testing of yeasts 2002, Approved standard NCCLS document M27-A2[S].
17. Jiang C., Dong D., Yu B., Cai G., Wang X., Ji Y., et al. Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother 2013, 68:778-785.
18. Skowronek P.K.G., Haferkamp O., Rodel G. Flow cytometry as a tool to discriminate respiratory-competent and respiratory-deficient yeast cells. Curr Genet 1990, 18:265-267.
19. Versalovic J., Koeuth T., Lupski J.R. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 1991, 19:6823-6831.
20. Xiang M.J., Liu J.Y., Ni P.H., Wang S., Shi C., Wei B., et al. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res 2013, 13:386-393.
21. Yoshida Y., Aoyama Y. Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes. Biochem Pharmacol 1987, 36:229-235.
22. Sanglard D., Odds F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002, 2:73-85.
23. Chau A.S., Mendrick C.A., Sabatelli F.J., Loebenberg D., McNicholas P.M. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004, 48:2124-2131.
24. Coste A.T., Karababa M., Ischer F., Bille J., Sanglard D. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 2004, 3:1639-1652.
25. Coste A., Turner V., Ischer F., Morschhauser J., Forche A., Selmecki A., et al. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 2006, 172:2139-2156.
26. Park S., Perlin D.S. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb Drug Resist 2005, 11:232-238.
27. White T.C., Holleman S., Dy F., Mirels L.F., Stevens D.A. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002, 46:1704-1713.
28. Vale-Silva L.A., Coste A.T., Ischer F., Parker J.E., Kelly S.L., Pinto E., et al. Azole resistance by loss of function of the sterol Delta(5),(6)-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob Agents Chemother 2012, 56:1960-1968.
29. Chau A.S., Gurnani M., Hawkinson R., Laverdiere M., Cacciapuoti A., McNicholas P.M. Inactivation of sterol Delta5,6-desaturase attenuates virulence in Candida albicans. Antimicrob Agents Chemother 2005, 49:3646-3651.